Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Darren Gitelman

Behavioral Neurology & Neuropsychiatry Park Ridge, IL Medical Doctor

NPI 1164530804 CMS profile 738314

1875 Dempster St Ste 520, Park Ridge, IL 60068

Open in the dashboard

General payments

$63,457

63 records reported · program years 2019–2025

Research payments

$44,348

Paid to them · 5 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$3,383,171 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Darren Gitelman of Park Ridge, IL is reported in the CMS Open Payments database as having received $63,457 across 63 general payments and $44,348 in research payments paid to them. Separately, studies naming them as principal investigator received $3,383,171 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Behavioral Neurology & Neuropsychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,609 2
2024 General $11,227 16
2023 General $40,706 27
2023 Research $300 1
2022 General $4,506 8
2022 Research $882 1
2021 General $3,419 5
2021 Research $43,042 2
2019 General $990 5
2019 Research $124 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Darren Gitelman
  • Behavioral Neurology & Neuropsychiatry median
  • Middle half of Behavioral Neurology & Neuropsychiatry
  • National median

In program year 2025, general payments to Darren Gitelman were reported at $2,609. Among 74 Behavioral Neurology & Neuropsychiatry profiles paid that year, the median was $152 and the middle half received between $53 and $1,035.

Show as a table
Year Darren Gitelman Behavioral Neurology & Neuropsychiatry median Middle half National median
2019 $990 $211 $86–$990 $163
2020 $0 $270 $54–$1,600 $114
2021 $3,419 $267 $60–$1,036 $132
2022 $4,506 $255 $69–$1,314 $149
2023 $40,706 $170 $50–$1,103 $160
2024 $11,227 $173 $39–$1,488 $164
2025 $2,609 $152 $53–$1,035 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Eli Lilly and Company $30,772 22 payments
  2. Eisai Inc. $15,746 10 payments
  3. AbbVie, Inc. $5,301 12 payments
  4. Biogen, Inc. $3,549 7 payments
  5. Lilly USA, LLC $3,544 2 payments
  6. E.R. Squibb & Sons, L.L.C. $2,019 3 payments
  7. Novo Nordisk Inc $1,500 3 payments
  8. Merck Sharp & Dohme Corporation $800 1 payment
  9. Genentech USA, Inc. $150 1 payment
  10. Genentech, Inc. $76 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $45,971 21 payments
  2. Travel and Lodging $12,701 11 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $3,390 2 payments
  4. Food and Beverage $1,290 24 payments
  5. Education $105 5 payments
Products named General payments · program years 2019–2025
  1. Leqembi $2,609 2 payments
  2. QULIPTA $800 1 payment
  3. MK-8931 $800 1 payment
  4. Non-Covered Product $76 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Eli Lilly and Company $44,224 4 payments
  2. AbbVie, Inc. $124 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

1,752

Median for Neuropsychiatry: 88

Drug cost

$91,062

Median for Neuropsychiatry: $2,689

Branded share of claims

23.6%

Median for Neuropsychiatry: 16.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Galantamine Er Galantamine Hbr Brand 271 $23,516
Rexulti Brexpiprazole Brand 13 $22,613
Rivastigmine Generic 59 $14,842
Memantine Hcl Generic 407 $13,151
Donepezil Hcl Generic 357 $4,806
Escitalopram Oxalate Generic 178 $2,001
Quetiapine Fumarate Generic 76 $1,358
Memantine Hcl Er Memantine Hcl Brand 19 $1,209
Mirtazapine Generic 24 $1,202
Carbidopa-Levodopa Carbidopa/Levodopa Brand 45 $1,075

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,891 Part D prescribers listed as Neuropsychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 16 billing codes

Paid by Medicare

$65,149

Medicare's payments for the services billed

Medicare patients

337

Average age 79

Services billed

1,094

169 women, 168 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Alzheimer's or dementia 74%
Arthritis 50%
Depression 42%
Ischemic heart disease 30%
Diabetes 29%
Chronic kidney disease 29%
Atrial fibrillation 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
QULIPTA
  • AbbVie, Inc. $800
$800 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

68 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Behavioral Neurology & Neuropsychiatry in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record